In osteosarcoma, ectopic expression of hsa-miR-433 decreased apoptosis in tumor cells by targeting programmed cell death 4 (PDCD4), indicating that hsa-miR-433 may be a potential molecular target for osteosarcoma treatment [38]. The gene discussed is PDCD4; the disease is neoplasm.